Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Aug;28(2):125–135. doi: 10.1111/j.1365-2125.1989.tb05404.x

L-648,051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man.

J M Evans 1, N C Barnes 1, J T Zakrzewski 1, D G Sciberras 1, E G Stahl 1, P J Piper 1, J F Costello 1
PMCID: PMC1379893  PMID: 2775617

Abstract

1. We have studied some of the pharmacological properties of inhaled L-648,051 which has been shown to be a selective cysteinyl-leukotriene (LT) antagonist in vitro and in vivo in various animal models. 2. The effects of three different doses (1.6, 6.0 and 12.0 mg) on the bronchoconstriction induced by inhaled LTD4 have been investigated in normal male subjects in a series of double-blind, placebo controlled studies. Furthermore, the specificity of the drug has been investigated by challenging subjects with histamine after pre-inhalation of 12.0 mg L-648,051. 3. At all doses L-648,051 partially blocked the bronchoconstriction induced by LTD4 inhalation in a dose related manner. At a dose of 12.0 mg, L-648,051 decreased the maximum fall in specific airways conductance (sGaw) (placebo, 49% vs L-648,051, 21%, P less than 0.01) and shortened the time to recovery from LTD4-induced bronchoconstriction (placebo, 41 min vs L-648,051, 19 min, P less than 0.01). 4. There was no evidence of partial agonist activity, and no effect on histamine-induced bronchospasm. Inhaled L-648,051 at all doses was well tolerated. 5. We conclude that LT antagonism is possible by the inhaled route in man. Inhaled L-648,051 is an active and selective LT-antagonist in man which is well tolerated and may prove to be a useful drug for assessing the role of leukotrienes in asthma and other lung diseases.

Full text

PDF
125

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelroth E., Morris M. M., Hargreave F. E., O'Byrne P. M. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med. 1986 Aug 21;315(8):480–484. doi: 10.1056/NEJM198608213150803. [DOI] [PubMed] [Google Scholar]
  2. Barnes N. C., Piper P. J., Costello J. F. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax. 1984 Jul;39(7):500–504. doi: 10.1136/thx.39.7.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barnes N., Piper P. J., Costello J. The effect of an oral leukotriene antagonist L-649,923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. J Allergy Clin Immunol. 1987 May;79(5):816–821. doi: 10.1016/0091-6749(87)90215-6. [DOI] [PubMed] [Google Scholar]
  4. Bisgaard H., Groth S., Madsen F. Bronchial hyperreactivity to leucotriene D4 and histamine in exogenous asthma. Br Med J (Clin Res Ed) 1985 May 18;290(6480):1468–1471. doi: 10.1136/bmj.290.6480.1468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bouhuys A., Hunt V. R., Kim B. M., Zapletal A. Maximum expiratory flow rates in induced bronchoconstriction in man. J Clin Invest. 1969 Jun;48(6):1159–1168. doi: 10.1172/JCI106073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Britton J. R., Hanley S. P., Tattersfield A. E. The effect of an oral leukotriene D4 antagonist L-649,923 on the response to inhaled antigen in asthma. J Allergy Clin Immunol. 1987 May;79(5):811–816. doi: 10.1016/0091-6749(87)90214-4. [DOI] [PubMed] [Google Scholar]
  7. Buckner C. K., Krell R. D., Laravuso R. B., Coursin D. B., Bernstein P. R., Will J. A. Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4. J Pharmacol Exp Ther. 1986 May;237(2):558–562. [PubMed] [Google Scholar]
  8. Cockcroft D. W., Berscheid B. A. Measurement of responsiveness to inhaled histamine: comparison of FEV1 and SGaw. Ann Allergy. 1983 Sep;51(3):374–377. [PubMed] [Google Scholar]
  9. Coles S. J., Neill K. H., Reid L. M., Austen K. F., Nii Y., Corey E. J., Lewis R. A. Effects of leukotrienes C4 and D4 on glycoprotein and lysozyme secretion by human bronchial mucosa. Prostaglandins. 1983 Feb;25(2):155–170. doi: 10.1016/0090-6980(83)90101-6. [DOI] [PubMed] [Google Scholar]
  10. Dahlén S. E., Björk J., Hedqvist P., Arfors K. E., Hammarström S., Lindgren J. A., Samuelsson B. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3887–3891. doi: 10.1073/pnas.78.6.3887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dahlén S. E., Hedqvist P., Hammarström S., Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980 Dec 4;288(5790):484–486. doi: 10.1038/288484a0. [DOI] [PubMed] [Google Scholar]
  12. GRIZZLE J. E. THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS. Biometrics. 1965 Jun;21:467–480. [PubMed] [Google Scholar]
  13. Holroyde M. C., Altounyan R. E., Cole M., Dixon M., Elliott E. V. Bronchoconstriction produced in man by leukotrienes C and D. Lancet. 1981 Jul 4;2(8236):17–18. doi: 10.1016/s0140-6736(81)90254-3. [DOI] [PubMed] [Google Scholar]
  14. Jones T. R., Guindon Y., Young R., Champion E., Charette L., Denis D., Ethier D., Hamel R., Ford-Hutchinson A. W., Fortin R. L-648,051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)- propylsulfonyl]-gamma-oxo-benzenebutanoate: a leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 1986 Dec;64(12):1535–1542. doi: 10.1139/y86-258. [DOI] [PubMed] [Google Scholar]
  15. Jones T. R., Young R., Champion E., Charette L., Denis D., Ford-Hutchinson A. W., Frenette R., Gauthier J. Y., Guindon Y., Kakushima M. L-649,923, sodium (beta S*, gamma R*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)- gamma-hydroxy-beta-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonist. Can J Physiol Pharmacol. 1986 Aug;64(8):1068–1075. doi: 10.1139/y86-183. [DOI] [PubMed] [Google Scholar]
  16. Lewis R. A., Austen K. F., Drazen J. M., Clark D. A., Marfat A., Corey E. J. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A. 1980 Jun;77(6):3710–3714. doi: 10.1073/pnas.77.6.3710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lewis R. A., Drazen J. M., Austen K. F., Clark D. A., Corey E. J. Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun. 1980 Sep 16;96(1):271–277. doi: 10.1016/0006-291x(80)91210-3. [DOI] [PubMed] [Google Scholar]
  18. Marom Z., Shelhamer J. H., Bach M. K., Morton D. R., Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 1982 Sep;126(3):449–451. doi: 10.1164/arrd.1982.126.3.449. [DOI] [PubMed] [Google Scholar]
  19. Morris H. R., Taylor G. W., Piper P. J., Tippins J. R. Structure of slow-reacting substance of anaphylaxis from guinea-pig lung. Nature. 1980 May 8;285(5760):104–106. doi: 10.1038/285104a0. [DOI] [PubMed] [Google Scholar]
  20. Russi E. W., Abraham W. M., Chapman G. A., Stevenson J. S., Codias E., Wanner A. Effects of leukotriene D4 on mucociliary and respiratory function in allergic and nonallergic sheep. J Appl Physiol (1985) 1985 Nov;59(5):1416–1422. doi: 10.1152/jappl.1985.59.5.1416. [DOI] [PubMed] [Google Scholar]
  21. Smith L. J., Greenberger P. A., Patterson R., Krell R. D., Bernstein P. R. The effect of inhaled leukotriene D4 in humans. Am Rev Respir Dis. 1985 Mar;131(3):368–372. doi: 10.1164/arrd.1985.131.3.368. [DOI] [PubMed] [Google Scholar]
  22. Snyder D. W., Krell R. D. Pharmacological evidence for a distinct leukotriene C4 receptor in guinea-pig trachea. J Pharmacol Exp Ther. 1984 Dec;231(3):616–622. [PubMed] [Google Scholar]
  23. Weiss J. W., Drazen J. M., Coles N., McFadden E. R., Jr, Weller P. F., Corey E. J., Lewis R. A., Austen K. F. Bronchoconstrictor effects of leukotriene C in humans. Science. 1982 Apr 9;216(4542):196–198. doi: 10.1126/science.7063880. [DOI] [PubMed] [Google Scholar]
  24. Weiss J. W., Drazen J. M., McFadden E. R., Jr, Weller P., Corey E. J., Lewis R. A., Austen K. F. Airway constriction in normal humans produced by inhalation of leukotriene D. Potency, time course, and effect of aspirin therapy. JAMA. 1983 May 27;249(20):2814–2817. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES